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Abstract
Background—Non-infectious wound complications (NIWCs) following mastectomy are not 
routinely tracked and data are generally limited to single-center studies. Our objective was to 
determine the rates of NIWCs among women undergoing mastectomy and assess the impact of 
immediate reconstruction (IR).
Study Design—We established a retrospective cohort using commercial claims data of women 
aged 18–64 years with procedure codes for mastectomy from 1/2004–12/2011. NIWCs within 180 
days after operation were identified by ICD-9-CM diagnosis codes and rates were compared 
among mastectomy with and without autologous flap and/or implant IR.
Results—18,696 procedures (10,836 [58%] with IR) among 18,085 women were identified. The 
overall NIWC rate was 9.2% (1,714/18,696); 56% required surgical treatment. The NIWC rates 
were 5.8% (455/7,860) after mastectomy-only, 10.3% (843/8,217) after mastectomy + implant, 
17.4% (337/1,942) after mastectomy + flap, and 11.7% (79/677) after mastectomy + flap and 
Corresponding Author: Margaret A. Olsen, PhD, MPH, Washington University School of Medicine, Division of Infectious Diseases, 
Campus Box 8051, 660 S. Euclid Ave., St. Louis, MO 63110, molsen@dom.wustl.edu, phone: (314) 454-8320 fax: (314) 454-5392. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosure Information: Nothing to disclose.
Disclosures outside the scope of this work: Dr Wallace is an employee of HealthCore, a wholly-owned subsidiary of Anthem, Inc., 
and has participated in an Anthem employee stock purchase plan.
Presented at the Pharmacoepidemiology & Therapeutic Risk Management 31st International Conference, Boston, MA, August 2015.
HHS Public Access
Author manuscript
J Am Coll Surg. Author manuscript; available in PMC 2017 May 01.
Published in final edited form as:
J Am Coll Surg. 2016 May ; 222(5): 844–852.e1. doi:10.1016/j.jamcollsurg.2016.01.050.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
implant (p<0.001). The rates of individual NIWCs varied by specific complication and procedure 
type, ranging from 0.5% for fat necrosis after mastectomy-only to 7.2% for dehiscence after 
mastectomy + flap. The percentage of NIWCs resulting in surgical wound care varied from 50% 
(210/416) for mastectomy + flap to 60% (507/843) for mastectomy + implant. Early implant 
removal within 60 days occurred after 6.2% of mastectomy + implant; 66% of the early implant 
removals were due to NIWCs and/or surgical site infection.
Conclusions—The rate of NIWC was approximately two-fold higher after mastectomy with IR 
than after mastectomy-only. NIWCs were associated with additional surgical treatment, 
particularly in women with implant reconstruction, and with early implant loss.
INTRODUCTION
Wound complications following breast surgical procedures, including surgical site infections 
(SSIs) and non-infectious wound complications (NIWCs), result in increased morbidity as 
well as increased healthcare utilization and costs.1 Wound complications can lead to worse 
outcomes after breast reconstruction including loss of implant or flap and poor cosmetic 
results,2–4 which often requires additional surgical procedures. Complications of breast 
reconstruction can result in large numbers of affected women, since over 26,000 breast 
reconstruction procedures were performed at the time of mastectomy during U.S. inpatient 
hospitalizations in 2012 (Healthcare Cost and Utilization Project National Inpatient 
Sample5). This number does not include subsequent reconstruction or procedures performed 
in ambulatory settings, and thus the total number of breast reconstruction procedures 
performed annually in the U.S. is much larger.
SSIs following breast procedures and healthcare facility surgical site infection rates are 
tracked nationally at over 14,500 facilities through the National Healthcare Safety Network 
(NHSN).6,7 Additionally, about 400 hospitals (most in the U.S.) participate in the American 
College of Surgeons National Quality Improvement Program (NSQIP), collecting data on 
process variables and 30-day complications, including SSIs.8 NSQIP collects NIWCs 
including wound dehiscence and return to the operating room, although the reason for 
reoperation is not specified. For breast reconstruction operations, loss of the flap or implant 
is also captured as a 30-day complication.9 Other than reports of wound dehiscence rates 
using the NSQIP database,10,11 reports of NIWC rates after breast procedures are generally 
limited to publications describing complications from a single surgeon or a large university-
affiliated hospital. Currently available literature on breast surgery complications is 
problematic because many publications report only one summary measure for complications 
after a variety of different breast reconstruction procedures (e.g., report one combined rate 
for immediate and delayed implant and autologous reconstructions), and do not compare 
complication rates after mastectomy with breast reconstruction to complication rates after 
mastectomy-only. In addition, different definitions of non-infectious complications are often 
used with various follow-up periods which makes it difficult to compare rates from various 
centers.
To provide more comprehensive data concerning the rates of NIWCs, including hematoma, 
fat necrosis, necrosis, and wound dehiscence after mastectomy with and without immediate 
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breast reconstruction, we identified wound complications in a large, geographically diverse 
cohort of women undergoing mastectomy, and assessed differences in outcome based on the 
type of immediate breast reconstruction performed.
METHODS
Data Source
We conducted a retrospective cohort study using the HealthCore Integrated Research 
Database (HIRDSM), including individuals from 12 Anthem-affiliated plans (California, 
Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the 
Kansas City area), Nevada, New Hampshire, New York, Ohio, Virginia (excluding the 
northern suburbs of Washington, DC). Data include all fully-adjudicated claims submitted 
from providers, facilities, and outpatient pharmacies linked to health plan enrollment 
information. Fully insured women with enrollment in a fee-for-service plan with medical 
coverage of hospital and physician services were eligible for inclusion in the study. We 
excluded women coded for end-stage renal disease, organ transplant, or HIV positive status 
due to unique risk factors for infection. Medical claims were restricted to paid claims.
The database contained up to 5 International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes per claim from 2004–2008 and up to 12 
diagnosis codes per claim from 2009–2011. Inpatient hospitals included up to 5 ICD-9-CM 
procedure codes per claim (8 in 2009–2011), while provider and ambulatory facility claims 
used CPT-4 (Current Procedural Terminology, 4th edition) codes.
To obtain hospital-level information, we matched the operative facility to the American 
Hospital Association Annual Survey of Hospitals (Health Forum, LLC, Chicago, IL) using 
National Provider Identifier codes, where available. Otherwise, matching to the AHA data 
was performed using facility name and address fields.
Identification of Mastectomy and Immediate Breast Reconstruction
We identified mastectomy operations among women aged 18–64 years from 1/1/2004–
12/31/2011 using ICD-9-CM and/or CPT-4 procedure codes from inpatient and outpatient 
facilities and provider claims (see Appendix). We classified the mastectomy as unilateral or 
bilateral based on the ICD-9-CM procedure and CPT-4 codes, billed units, and CPT-4 
modifier codes assigned by the provider and facility.12 Operations in members whose 
enrollment ended on the day of mastectomy were excluded since no follow-up was available. 
When CPT-4 or ICD-9-CM procedures codes for breast conserving surgery (BCS) were 
present during the same hospital admission or within +/− 3 days of mastectomy, we used an 
algorithm to determine whether BCS or mastectomy was more likely, as described 
previously.12 We excluded procedures that were more consistent with BCS, since concurrent 
BCS and mastectomy is unlikely and the incidence of SSI after BCS is lower than after 
mastectomy.12,13 We defined immediate reconstruction (IR) as the presence of CPT-4 and/or 
ICD-9-CM procedure codes for tissue expander/breast implant and/or flap reconstruction 
within +/− 7 days of the mastectomy (see Appendix), with prioritization of the provider 
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classification of the type of flap when there was a discrepancy. Delayed reconstruction 
procedures were excluded since our focus was on NIWCs associated with mastectomy.
Identification of Wound Complications
NIWCs first coded from 2–180 days (1–180 days for hematoma) after surgery were 
identified using ICD-9-CM diagnosis codes from inpatient and outpatient facilities and 
provider claims. NIWCs included fat necrosis (ICD-9-CM diagnosis codes 567.82, 611.3), 
dehiscence (875.0, 875.1, 879.0, 879.1, 998.3, 998.32), hematoma (998.12), and necrosis 
(998.83). We excluded claims with laboratory or patient’s home locations and provider 
claims with laboratory CPT-4 codes (88104–88399), since these diagnosis codes may have 
indicated diagnostic workup and not post-surgical complications. For women with 
autologous flap reconstruction, the site of NIWC (donor vs. flap) could not be determined, 
since ICD-9-CM diagnosis codes do not distinguish the site of complication.
The date of onset of NIWCs was defined according to the timing and location of diagnosis. 
For NIWCs coded by an inpatient facility during the original operative admission, we 
assigned the date of NIWCs to the discharge date if the difference between the discharge and 
admission date was greater than or equal to 2 days. For NIWCs diagnosed during a 
subsequent inpatient admission, the date of NIWCs onset was assumed to be the date of 
hospital readmission. For NIWCs diagnosed initially by a provider or in an outpatient 
setting, the onset date was defined as the first service date coded for the NIWC.
The observation period for NIWCs was through 180 days after surgery, with earlier 
censoring for the end of insurance enrollment, a subsequent mastectomy, implant, flap, or 
nipple reconstruction. We censored one day after the subsequent surgery since we assumed 
that an NIWC coded on the day of or one day after a surgical procedure was preexisting and 
could be attributed to the previous surgery. Non-breast specific NIWC codes (e.g., 998.12, 
998.3, 998.32, 998.83) were not classified as an NIWC if they were first coded after a 
subsequent non-breast operation, defined using the National Healthcare Safety Network 
procedure list.6
Preexisting NIWCs—ICD-9-CM diagnosis codes for NIWCs (other than hematoma) 
coded from 30 days before to 1 day after mastectomy were considered preexisting and were 
not used as evidence of a new-onset NIWC. For operations with a preexisting NIWC, we 
required a 30 day gap with no coding of an NIWC following the operation in order to 
identify an incident NIWC.
NIWC Requiring Surgical Wound Care—Surgical wound care within 14 days (and 
before applicable censoring) of an NIWC included CPT-4 codes 10140, 10160, 11000, 
11001, 11040– 11044, 10060, 10061, 10180, 11005, 11008, 19020, 20000, 20005, 38300, 
38305, A6550, A6551, E2402, and K0538 and ICD-9-CM procedure codes 54.0, 54.3, 
83.44, 83.45, 83.49, 85.0, 86.04, 86.09, and 86.22. For mastectomy with immediate implant, 
we also included breast implant removal (CPT-4 11971, 19328; ICD-9-CM 85.94, 85.96), 
implant exchange (CPT 11970); or breast implant removal plus implant insertion (CPT-4 
19325, 19340, 19342, 19357; ICD-9-CM 85.33, 85.35, 85.53, 85.54, 85.95) within 14 days 
(and before applicable censoring) of an NIWC as evidence of surgical wound care.
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SSIs first coded from 2 to 180 days after surgery were identified using ICD-9-CM diagnosis 
codes from inpatient and outpatient facilities and provider claims (see Appendix), as 
described previously.12
Early Implant Loss, Physician and Emergency Department Encounters
We defined early implant loss as a breast implant removal, with or without an implant 
exchange, within 60 days of a mastectomy with implant IR. We used the CPT-4 and ICD-9-
CM procedure codes described in the previous section. Codes for SSI or NIWCs in the 14 
days prior to removal were considered the indication for implant removal. To compare 
outpatient utilization, we identified distinct dates with CPT-4 codes for physician office 
visits (99201–99215) and emergency department encounters (99281–99285).
Statistical Analysis
The rates of NIWCs overall and by type of complication within 180 days after surgery for 
mastectomy with and without IR were compared using a Chi-square test, as were other 
categorical variable comparisons. For the comparisons of wound complication rates by type 
of procedure, the alpha was adjusted for multiple testing using the Bonferroni method.14 We 
used the Kruskal-Wallis test to compare continuous variables. All data management and 
statistical analyses were performed using SAS v9.3 (SAS Institute Inc., Cary, NC). This 
study was approved by the Washington University Human Research Protection Office.
RESULTS
Overall Rates of NIWCs
The final analysis sample included 18,696 mastectomy procedures among 18,085 women. 
The median age of women was 51 years (interquartile range 45–57 years). The indication for 
mastectomy was cancer in 17,861 (95.5%), and prophylactic or benign conditions in 835 
(4.5%). Forty-two percent of the operations were mastectomy-only, 44.0% mastectomy plus 
implant IR, 10.4% mastectomy plus flap IR, and 3.6% were categorized as mastectomy plus 
flap and implant IR (Table 1). As reported previously, 39% of procedures were bilateral and 
81% were performed on during an inpatient admission.12 Among procedures performed 
during an inpatient hospital stay that we could link to the AHA survey (n=11,756; 63%), 
50% were performed at a hospital with a residency training program and 58% at a hospital 
with a medical school affiliation. Thirty-nine percent of procedures were performed at a 
hospital with <300 beds, 33% at a hospital with 300–499 beds, and 28% at a hospital with ≥ 
500 beds. Most procedures were performed at an urban hospital (94%), and the procedures 
were distributed across the U.S. (18% Northeast, 34% South, 26% Midwest, and 21% West).
The overall NIWC rate following mastectomy with and without IR was 9.2% 
(1,714/18,696); 56% of the NIWCs required a surgical wound care procedure. The rates of 
NIWCs were 5.8% after mastectomy-only, 10.3% after mastectomy with implant, 17.4% 
after mastectomy with flap, and 11.7% after mastectomy with flap and implant (p<0.001, 
Chi-square test; Table 1). The risk of an NIWC was almost 2-fold higher after mastectomy 
plus implant and 3-fold higher after mastectomy plus flap compared with mastectomy-only. 
The rates of NIWCs requiring surgical wound care ranged from 3.0% after mastectomy-only 
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to 8.3% for mastectomy with flap reconstruction (Table 1). The proportion of NIWC 
diagnosed during a hospitalization (index or readmission) varied from 28% after 
mastectomy plus implant to 39% after mastectomy plus flap.
Effect of Uni- Versus Bilateral Procedures
Among mastectomies with IR, the NIWC rate was significantly higher after bilateral 
compared with unilateral procedures (12.7% (703/5,529) vs. 10.5% (556/5,307) respectively, 
p<0.001, Chi-square test). Similarly, among mastectomies without IR, the NIWC rate was 
significantly higher after bilateral compared with unilateral procedures (8.1% (141/1,739) 
vs. 5.1% (314/6,121), p<0.001, Chi-square test).
Complication Rates and Indication for Mastectomy
The rates of NIWCs were similar for women with cancer versus prophylaxis or benign 
conditions (9.2% vs. 8.9%, p=0.75, Chi-square test). NIWC after mastectomy-only occurred 
in 5.7% (439/7,639) of women with breast cancer (in situ or invasive) and 7.2% (16/221) of 
women undergoing mastectomy for prophylaxis or benign conditions (p=0.35, Chi-square 
test). Among mastectomy + IR, 11.7% (1,201/10,222) of procedures were complicated by 
NIWC in women with cancer versus 9.4% (58/614) of procedures performed for prophylaxis 
or benign conditions (p=0.08, Chi-square test).
Association with Surgical Site Infection
Of 1,714 mastectomy procedures complicated by an NIWC, 29% were also coded for an SSI 
within 180 days after surgery. Among procedures with both an NIWC and SSI, the most 
common NIWCs were dehiscence (60.9%) and necrosis (35.3%). Among those procedures 
with both an SSI and an NIWC, 36% were coded for both complications at the same time, 
while the NIWC preceded SSI by more than one day in 36% of procedures (Table 2). The 
most common timing of wound complications after mastectomy-only and mastectomy with 
flap was coding of NIWC before SSI, while SSI and NIWC after mastectomy with implant 
IR most commonly was coded simultaneously (Table 2). For this and subsequent analyses, 
mastectomy with immediate flap included flap with or without concurrent implant because 
of the small number of immediate flap plus implant procedures.
Effect on Sustainability of Reconstruction
Among mastectomy with immediate implant reconstruction, 216 (2.6%) had implant 
removal within 30 days and 506 (6.2%) had implant removal within 60 days after 
mastectomy, with or without implant exchange. Sixty-six percent of women with an early 
implant removal within 60 days were coded for an SSI or NIWC in the 14 days before 
implant removal. Fourteen percent of the procedures with early implant removal were coded 
for both SSI and NIWC (n = 73), 43.1% (n = 218) were coded for SSI only, and 8.5% (n= 
43) were coded for NIWC only. The remaining 34.0% (n = 172) of procedures with early 
implant removal were not coded for either an infectious or noninfectious wound 
complication in the two weeks before implant removal. Of these early implant removals 
without wound complication per our definition, 59.3% (n = 102) were coded for another 
complication (e.g., malfunction or complication of prosthetic device, deformity/
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disproportion of reconstructed breast, breast pain, seroma). In addition, women with NIWCs 
had significantly more physician visits within 180 days after operation compared to women 
without a wound complication (median 8 vs. 7 visits on distinct dates, p<0.001, Kruskal-
Wallis test) and more emergency department (ED) encounters (median 0 for both, mean 0.4 
vs. 0.2 ED encounters, p<0.001, Kruskal-Wallis test).
Timing of Incident NIWCs
The median time to diagnosis of NIWCs was significantly shorter following mastectomy-
only compared with mastectomy plus implant or mastectomy plus flap (median 17 vs. 24 
and 29 days respectively; p<0.001, Kruskal-Wallis test). NIWCs were first coded within 30 
days after mastectomy-only in 65.7% of procedures, with 17.1% diagnosed between 31–60 
days. Among mastectomy with IR, NIWCs were first coded within 30 days in 58.2% of 
procedures and 20.7% were diagnosed between 31–60 days (Figure 1).
Rates of NIWCs by Procedure Type
Individual complication rates ranged from 0.5% for fat necrosis after mastectomy-only to 
7.2% for dehiscence after mastectomy with flap reconstruction (Table 3). The fat necrosis, 
dehiscence, and necrosis NIWC rates were all significantly higher after mastectomy plus 
implant and mastectomy plus flap compared with the individual NIWC rates after 
mastectomy-only. The proportion of operations complicated by hematoma was significantly 
higher after mastectomy plus flap, but not mastectomy plus implant compared to 
mastectomy-only. Among mastectomy with reconstruction, the rates of all NIWC categories 
were significantly higher after flap versus implant reconstruction. Overall the median time to 
NIWC diagnosis ranged from 7 days for hematoma to 35 days for fat necrosis (Table 3).
DISCUSSION
We demonstrated that the overall NIWC rate after mastectomy was almost 10% in our 
sample of 18–64 year old women with private insurance undergoing mastectomy from 
2004–2011, and complication rates were significantly higher after mastectomy with IR 
compared with mastectomy-only for all individual NIWCs except hematoma. Immediate 
flap reconstruction (with or without implant) was associated with significantly higher rates 
of fat necrosis, dehiscence, hematoma, and necrosis compared with immediate implant 
reconstruction. The increased rates of NIWCs after mastectomy with flap may be a 
reflection of the more prolonged surgical procedure time, longer incision and multiple 
surgical sites involved with performing a flap procedure compared to the time and incisions 
involved performing mastectomy with implant reconstruction.
The rates of several NIWCs identified in this private insurer data were at the upper end of 
the range of reported rates from clinical studies in the literature (Table 4). For example, we 
identified dehiscence/open wound within 180 days after 5.1% of mastectomy plus implant 
IR procedures, compared to 0.6% to 6.2% in single-center reports in the literature.15–24 
Similarly, we identified hematoma in 2.6% of mastectomy plus implant and 3.7% of 
mastectomy plus flap IR, while the majority of studies in the literature reported lower 
hematoma rates for these procedures.18,21–42 Rates for dehiscence/wound disruption and 
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implant/flap loss are also available from the NSQIP database. In the most recent analysis of 
complication rates after mastectomy with IR, dehiscence was recorded within 30 days after 
0.6% of immediate implant and 0.9% of immediate flap reconstructive procedures.11
The complication rates we report are likely higher than rates reported in many clinical 
studies and from the NSQIP data for a number of reasons, including the longer time period 
of observation in our study (180 compared to 30 days for NSQIP). We identified 
complications in all settings using the medical claims, including outpatient clinic and 
emergency department encounters, some of which may have been missed in previous studies 
if patients presented to physicians other than their general or plastic surgeon. We also 
identified all complications regardless of severity, whereas in some clinical studies primarily 
severe complications were recorded.22,30,32,33,39–42 In our study, 44% of NIWCs did not 
have evidence of subsequent surgical wound care, so the inclusion of potentially 
conservatively-treated NIWCs may have increased the NIWC rates in our study by up to 
two-fold. Many of the publications reporting rates of complications from individual 
institutions reported rates per breast rather than per person, resulting in lower complication 
rates, particularly in studies with high proportions of bilateral 
procedures.15–22,24,25,27,29,31–38,41–43,45
We found that implant removal occurred in 2.6% of mastectomy plus implant within 30 days 
and in 6.2% within 60 days of operation. This is higher than the 0.65% implant loss rate 
reported recently using 2005–2013 NSQIP data.11 The rate of implant loss in our study is 
higher than some17,21,31,33,38,40 but not all16,22,23,30,35,36,42 studies reported in the last 
decade from individual U.S. institutions, although the timing of implant removal was not 
described in these studies. We found that 58% of operations complicated by early implant 
loss were associated with SSI, either alone or in combination with NIWC, and an additional 
9% were associated with NIWC alone. In a recent analysis of the NSQIP data, Fischer and 
colleagues found that SSIs were implicated in 17.7% of implant loss within 30 days in 
patients who had immediate implant reconstruction, while dehiscence was present in 2.4% 
of the patients with implant loss.46
Nearly 30% of procedures coded for NIWCs were also coded for SSIs. The timing of SSIs 
and NIWCs varied slightly by procedure, with NIWCs coded most often before SSIs after 
mastectomy- only and after mastectomy plus flap, while SSIs and NIWCs were most often 
coded concurrently after mastectomy plus implant IR. Hematoma was the most common 
NIWC after mastectomy-only, with a median time to diagnosis of 7 days after operation. 
This result is also consistent with the finding of Al-Hilli et al. that bleeding was responsible 
for two-thirds of reoperation after mastectomy-only using the 2012 NSQIP data.47 In 
contrast, the most common NIWC in our study after mastectomy with implant 
reconstruction was dehiscence, with median time to onset of 32 days after operation, 
virtually the same as the median 33 days to onset of SSI after mastectomy with IR we 
reported previously in this population.12 Thus our finding that concurrent SSI and NIWC 
was most common after mastectomy with implant reconstruction is consistent with the 
timing and distribution of the individual NIWCs after operation.
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The strengths of this study include the large number of women who underwent mastectomy 
and high proportion with IR in this younger privately insured population. We identified 
complications up to 180 days after surgery and found that 40% of complications were 
detected more than one month after surgery. NSQIP surveillance for non-infectious 
complications could be improved by increasing the duration of surveillance of complications 
for reconstructive procedures, and collecting the reason for return to the operating room. 
Limitations include the use of claims data to identify NIWCs, which by definition involves 
secondary analysis of data collected for billing purposes. There is potential for 
misclassification of diagnoses and likely undercoding of NIWCs, particularly minor 
complications during the 90 day global surgical reimbursement period for providers.48 
Although we have previously validated the ICD-9-CM diagnosis codes for SSI,49 no 
validation of the diagnosis codes for the NIWCs used in this study has been reported. For 
mastectomy plus flap reconstruction, we were not able to determine the rates of NIWCs at 
the mastectomy and donor flap sites because site of complication is not available with claims 
data. Finally, since our analysis sample was restricted to women with private insurance <65 
years of age, generalizability to women with other types or lack of health insurance and to 
older women is unknown.
We demonstrated that the rate of noninfectious wound complications was two-fold higher 
after mastectomy with IR compared to mastectomy-only, and the distribution of specific 
complications was different depending on the use and type of reconstruction. Over half of 
the NIWCs were associated with additional surgical wound care and almost one-third of 
NIWCs occurred in women with SSI. Further work is needed to identify risk factors for 
noninfectious wound complications in women undergoing these procedures to determine the 
best strategies to prevent these complications. Prevention of both infectious and 
noninfectious wound complications after mastectomy, particularly in women with IR, is 
important to avoid potential longer term adverse consequences, including implant/flap loss, 
delays in oncologic treatment, and additional surgical procedures, which may be necessary 
to improve cosmetic outcomes. Our findings may be helpful in guiding patients as they 
balance the risk of complications and surgical treatment options (e.g., breast conservation, 
uni- and bilateral mastectomy, immediate and delayed reconstruction) against their personal 
preferences, expectations, and practical considerations (e.g., support system at home, out-of-
pocket costs).
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CPT-4 Current Procedural Terminology, 4th edition
HIRDSM HealthCore Integrated Research Database
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification
IR immediate reconstruction
NHSN National Healthcare Safety Network
NIWC non-infectious wound complication
NSQIP National Surgical Quality Improvement Program
SSI surgical site infection
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APPENDIX 1. Procedure Codes Used to Identify Mastectomy and Immediate 
Reconstruction Procedures
Operative Category ICD-9-CM Procedure Code CPT-4 or HCPCS Procedure
Code
Mastectomy* 85.41–85.48 19180, 19200–19240, 19303,
19305–19307
Breast implant 85.33, 85.35, 85.53, 85.54, 85.95 19325, 19340, 19342, 19357
Flap reconstruction 85.7–85.79, 85.85 19361, 19364, 19367–19369,
S2066–S2068
CPT-4 indicates Current Procedural Terminology, 4th edition; HCPCS, Healthcare Common Procedure Coding System; 
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification.
*
For mastectomy coded by facility- or provider-only, a code for anesthesia (CPT-4 00400– 00406), pathology (CPT-4 
88307, 88309), or a surgery revenue code (Uniform Billing 0201, 0360, 0361, 0369, 0370, 0379, 0490, 0499, 0963, 0964, 
0975) was required as evidence for surgery.
APPENDIX 2. Procedure and Diagnosis Codes Used in Combination to 
Identify Surgical Site Infection Following Mastectomy With and Without 
Immediate Reconstruction
ICD-9-CM
Diagnosis Code
CPT-4 or HCPCS
Procedure Code
ICD-9-CM
Procedure Code
Breast-specific codes
Infection, lymphadenitis 611.0, 683.0,
996.69*
Incision/drainage†, ‡ 19020, 38300, 38305 85.0, 85.91
Non-infectious wound
complication†
611.3, 875.0, 875.1,
879.0, 879.1
Breast implant removal‡ 11971, 19328 85.94, 85.96
General codes§
Postoperative infection 998.5–998.59
Cellulitis† 682.2, 682.3, 682.9∥
Staphylococcus aureus‡,¶ 041.1–041.19
Incision/drainage†, ‡ 10060, 10061,
10140–10180,
11000, 11001,
11005,# 11008,#
11040–11044,
20000, 20005,
A6550, A6551,
E2402, K0538
54.0,# 54.3,# 83.44–
83.49, 86.01, 86.04,
86.09, 86.22, 86.28
Non-infectious wound
complication†
567.82,# 998.12,
998.3, 998.32,
998.83
CPT-4 indicates Current Procedural Terminology, 4th edition; HCPCS, Healthcare Common Procedure Coding System; 
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification.
*
ICD-9-CM diagnosis code 996.69 was excluded if it was coded before a breast implant or flap reconstruction procedure or 
if it was on a claim with pathology code 88300 on the same day as a catheter removal (because 996.69 could be referring to 
an infection found on gross examination of the catheter).
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†Codes were used in combination with an ICD-9-CM diagnosis code for Staphylococcus aureus.
‡Codes were used in combination with an ICD-9-CM diagnosis code for cellulitis.
§
Excluded if occurred +/− 7 days of an SSI code that was specific to another type of device (ICD-9-CM 996.61–996.68, 
999.31) while a catheter was in place.
∥
Diagnosis code 682.9 codes for cellulitis and abscess at an unspecified site; it was used only if it was on the same claim 
line as a breast-specific incision/drainage code, on the same day as an implant removal, or coded by the patient’s breast 
surgeon.
¶A S. aureus diagnosis code associated with an incision/drainage code was only used if the incision/drainage code was 
breast-specific or coded by the patient’s breast surgeon.
#
Excluded if coded before a non-latissimus dorsi flap reconstruction procedure.
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Figure 1. 
Days to Non-Infectious Wound Complications (NIWC) Following Mastectomy With and 
Without Immediate Reconstruction (n = 1,714 NIWC).
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TABLE 1
Rates of Non-Infectious Wound Complications (NIWC) After Mastectomy With and Without Immediate 
Reconstruction (IR)
Operative
Category
Total
Procedures (n=
18,696), n
(column %)
NIWC
Requiring
Surgical Wound
Care* (n= 953),
n (row %)
Any NIWC
(n=1,714),
n (row %)
Relative Risk of
Any NIWC
(95% CI)**
Mastectomy-only 7,860 (42.0) 236 (3.0) 455 (5.8) 1.00
Mastectomy with
implant IR
8,217 (44.0) 507 (6.2) 843 (10.3) 1.77 (1.59, 1.98)
Mastectomy with
flap IR
1,942 (10.4) 162 (8.3) 337 (17.4) 3.00 (2.63, 3.42)
Mastectomy with
flap + implant
IR
677 (3.6) 48 (7.1) 79 (11.7) 2.02 (1.61, 2.53)
Mastectomy with
IR
10,836 (58.0) 717 (6.6) 1,259 (11.6) 2.01 (1.81, 2.23)
*Surgical wound care performed at the bedside or operating room
**All comparisons significant after adjustment for 4 tests (p < 0.0125). Relative risk calculated by dividing the rate of NIWCs among mastectomy 
+ IR by the rate of NIWCs among the mastectomy-only reference group.
CI indicates confidence interval.
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TABLE 2
Co-Occurrence of Noninfectious Wound Complication (NIWC) and Surgical Site Infection (SSI) by Operative 
Category
Operative
Category
(n of total NIWC)
NIWC + SSI, n
(% of total
NIWC)
NIWC + SSI, n (row %)*
NIWC
Before SSI
NIWC at Same
Time as SSI**
NIWC
After SSI
Mastectomy-only
(n = 455)
105 (23.1) 41 (39.0) 27 (25.7) 37 (35.2)
Mastectomy with
implant IR
(n = 843)
265 (31.4) 87 (32.8) 109 (41.1) 69 (26.0)
Mastectomy with
flap IR† (n = 416)
129 (31.0) 53 (41.1) 42 (32.6) 34 (26.4)
Mastectomy with
IR (n = 1,259)
394 (31.3) 140 (35.5) 151 (38.3) 103 (26.1)
Total NIWC
(n = 1,714)
499 (29.1) 181 (36.3) 178 (35.7) 140 (28.1)
*
Percentage of the total coded for both NIWC and SSI within operative category.
**SSI within ± 1 day of the NIWC
†
Flap IR with or without concurrent implant reconstruction.
IR, immediate reconstruction.
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TABLE 4
Summary of Noninfectious Wound Complication Rates after Immediate Breast Reconstruction in the Surgical 
Literature from Individual Institutions
Implant Reconstruction Flap Reconstruction
Wound
Complication Literature This Study Literature This Study
Dehiscence/ Wound
Disruption/
Exposure/ Open
Wound, %
0.6–6.215–24 5.1 0.9–4.016,18 7.2
Implant/Flap Loss, % 1.0–21.416,17,21–23,30,31,33–36,38,40,42,44 6.2 0–4.815,18,25,26,37
Necrosis, % 1.0–18.317,18,20–24,28–36,38,40–42,45 2.4 3.3–16.618,25–28,37,39 4.7
Hematoma, % 0–2.918,21–24,28–36,38,40–42 2.6 0.5–3.918,25–28,37,39 3.7
Fat Necrosis, % 1.9 2.8–24.415,18,25–27,37,43 5.3
J Am Coll Surg. Author manuscript; available in PMC 2017 May 01.
